Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
The anti-CD38 monoclonal antibody daratumuÂmab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition.
The ASCO Post
In The News
American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting